Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03992755 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

StatusActive, Not Recruiting
PhasePhase 3
Started2019-07-18
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 29, 2025 (before its estimated May 31, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2025-01-28
Study Status v4
Primary completion date2021-12-31→2025-05-31
Completion date2022-03-30→2025-05-31
2021-08-26
Study Status v3
Re-verified, no change to tracked fields
2020-04-14
Enrolling by Invitation→Active, Not Recruiting Study Status, Study Design v2
Trial statusEnrolling by Invitation→Active, Not Recruiting
Enrollment targetestimated 150→confirmed 92
2019-09-11
Not Yet Recruiting→Enrolling by Invitation Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Enrolling by Invitation
Start dateestimated 2019-06-24→confirmed 2019-07-18
2019-06-18
Original filing
The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
Trial Details
NCT Number NCT03992755
Lead Sponsor Liquidia Technologies, Inc.
Collaborators: Nuventra, Inc.
Conditions Primary Pulmonary Hypertension
Enrollment 92 participants
Start Date 2019-07-18
Primary Completion 2025-05-31 (estimated)
Study Completion 2025-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-29